Pharma News

A groundbreaking study presented at the highly anticipated 2024 European Lung Cancer Congress (ELCC) has unveiled encouraging results regarding the efficacy of AkesoBio's "PD-1/VEGF bispecific antibody," known as Ivonescimab.

Hengrui Pharmaceuticals has recently unveiled the latest data from their innovative drug, Carrelizumab.

Stemirna Therapeutics, a leading biotechnology company, has announced the suspension of its groundbreaking mRNA personalized cancer vaccine, SW1115C3.

In an unprecedented achievement, a prominent biotech company has reported a staggering surge in performance, with revenues skyrocketing by 3.7 billion yuan. This remarkable feat marks Akeso Biopharma's first-ever annual profit since its inception.

In a groundbreaking deal, global pharmaceutical giant AstraZeneca has announced its acquisition of Fusion Pharmaceuticals, a leading nuclear medicine company, for a staggering $2.4 billion.

Qyuns Therapeutics, commonly known as the "Self-Immunity Pioneer," commenced trading on the Hong Kong Stock Exchange today.

Everest Medicines announced that Nefecon®, their groundbreaking drug for the treatment of primary IgA nephropathy in adults at risk of disease progression, has received approval from the Health Sciences Authority (HSA) in Singapore.

In a dramatic turn of events, the biotech industry has witnessed a power struggle that resulted in the ousting of a prominent founder.

In the ever-evolving landscape of the pharmaceutical industry, the pursuit of patents has become a critical aspect of competition for drug companies.

BIO-THERA Pharmaceuticals, a leading biopharmaceutical company, has recently announced a major milestone in its global expansion strategy.

New RadioMedicine Technology, a leading healthcare company specializing in the research, development, and industrialization of radiopharmaceuticals, has successfully secured over 300 million yuan in Series C funding.

Contineum Therapeutics, a leading biotechnology company based in the United States, has recently submitted its Initial Public Offering (IPO) application, signaling its intention to go public on the Nasdaq stock exchange.

WuXi AppTec, a leading pharmaceutical company, has announced its impressive financial results for the year 2023. With remarkable growth in revenue and net profit, the company has achieved a significant milestone in its history.

Peptides have emerged as a revolutionary force in the field of pharmaceuticals, consistently gaining recognition in clinical settings and experiencing exponential market growth.

BIO-THERA and SteinCares, two prominent biotech companies, have recently entered into a significant licensing and commercialization agreement worth $6 million.

Mabwell Biotechnology unveiled groundbreaking clinical data on their targeted therapy, Nectin-4 ADC, for the treatment of cervical cancer.

In a recent strategic partnership, CanSino Biologics (Shanghai) Biotechnology Co., Ltd. and Shanghai AsymBio Biotechnology Co., Ltd. have joined forces to focus on the advancement of mRNA technology.

"TROP 2 ADC" has achieved formal acceptance by the China Drug Administration (CDE) for the treatment of advanced breast cancer.

Novartis, a leading pharmaceutical company, recently announced its acquisition of IFM Due, a subsidiary of IFM Therapeutics, in a deal worth $835 million.

In just two years, Apogee has achieved a staggering market value of $4 billion. This remarkable success story revolves around a meticulously planned "biotech experiment."